Serological Response to SARS-CoV-2 in Health Care Workers Employed in a Large Tertiary Hospital in Lombardy, Northern Italy.
COVID-19
SARS-CoV-2 infection
health care workers
seroprevalence
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
25 Feb 2021
25 Feb 2021
Historique:
received:
01
02
2021
revised:
21
02
2021
accepted:
22
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
7
3
2021
Statut:
epublish
Résumé
COVID-19 pandemic is requesting unprecedented efforts by health-care workers (HCWs) in all countries, and especially in Italy during the first semester of 2020. This is a retrospective, observational study conducted at the Spedali Civili General Hospital, in Brescia, Northern Italy during the SARS CoV-2 pandemic in the first semester of 2020. Serum samples from HCWs were tested for SARS-CoV-2 spike protein-specific antibodies. An online survey was used to collect demographic, clinical, and epidemiological data. Of the 1893 HCWs included, 433 (22.9%) were found seropositive for SARS-CoV-2 IgG. The cumulative prevalence of SARS-CoV-2 infection (antibodies production or past positive RT-PCR on nasal/throat swab) was 25.1% (475/1893). Fifty-six out of 433 (13%) seropositive participants declared to have been asymptomatic during the study period. The development of COVID-19 signs or symptoms is the main determinant of seropositivity (OR: 11.3, In this study, carried out in one of the most affected areas in Europe, we demonstrate that most HCWs with COVID-19 related symptoms develop a spike protein-specific antibodies with potential neutralizing effect.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19 pandemic is requesting unprecedented efforts by health-care workers (HCWs) in all countries, and especially in Italy during the first semester of 2020.
METHODS
METHODS
This is a retrospective, observational study conducted at the Spedali Civili General Hospital, in Brescia, Northern Italy during the SARS CoV-2 pandemic in the first semester of 2020. Serum samples from HCWs were tested for SARS-CoV-2 spike protein-specific antibodies. An online survey was used to collect demographic, clinical, and epidemiological data.
RESULTS
RESULTS
Of the 1893 HCWs included, 433 (22.9%) were found seropositive for SARS-CoV-2 IgG. The cumulative prevalence of SARS-CoV-2 infection (antibodies production or past positive RT-PCR on nasal/throat swab) was 25.1% (475/1893). Fifty-six out of 433 (13%) seropositive participants declared to have been asymptomatic during the study period. The development of COVID-19 signs or symptoms is the main determinant of seropositivity (OR: 11.3,
CONCLUSIONS
CONCLUSIONS
In this study, carried out in one of the most affected areas in Europe, we demonstrate that most HCWs with COVID-19 related symptoms develop a spike protein-specific antibodies with potential neutralizing effect.
Identifiants
pubmed: 33669151
pii: microorganisms9030488
doi: 10.3390/microorganisms9030488
pmc: PMC7996483
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
Blood Transfus. 2021 Feb 03;:
pubmed: 33539289
J Clin Virol. 2020 Aug;129:104545
pubmed: 32659709
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet. 2020 May 2;395(10234):1418-1420
pubmed: 32305073
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
PLoS One. 2020 Jun 25;15(6):e0235417
pubmed: 32584894
Euro Surveill. 2020 Jun;25(24):
pubmed: 32583766
Infect Control Hosp Epidemiol. 2021 Feb;42(2):212-214
pubmed: 32746953
MMWR Morb Mortal Wkly Rep. 2020 Sep 04;69(35):1221-1226
pubmed: 32881855
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32580948
JAMA. 2020 Jul 14;324(2):195-197
pubmed: 32539107
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
J Hosp Infect. 2020 Aug;105(4):596-600
pubmed: 32565367
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Lancet Infect Dis. 2020 Sep;20(9):1043-1050
pubmed: 32539988
J Hosp Infect. 2020 May 30;:
pubmed: 32485198
Clin Infect Dis. 2020 Jul 06;:
pubmed: 32628750
Nat Rev Immunol. 2020 Oct;20(10):583-584
pubmed: 32908300
Clin Infect Dis. 2020 Nov 5;71(8):1930-1934
pubmed: 32306047
J Crit Care. 2020 Aug;58:29-33
pubmed: 32330817
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):411-415
pubmed: 32271722
Int J Environ Res Public Health. 2020 Jun 19;17(12):
pubmed: 32575505
Infez Med. 2020 Ahead of print Jun 1;28(2):133-134
pubmed: 32275253
Int J Emerg Med. 2020 Jul 20;13(1):40
pubmed: 32689925
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708